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Introduction
Epithelial cells are joined to each other by junctional complexes 
that mediate cell–cell adhesion but also regulate cell prolifera-
tion and differentiation. Tight junctions, the most apical junc-
tions, form the apical junctional complex together with adherens 
junctions. They form paracellular diffusion barriers required 
for functional epithelial tissues (Steed et al., 2010; Shen et al., 
2011). Tight junctions are composed of transmembrane compo-
nents and a complex submembrane plaque of proteins that link 
the junction to the cytoskeleton (Furuse and Tsukita, 2006; Van 
Itallie and Anderson, 2006; Balda and Matter, 2008). Tight 
junctions and components of the submembrane plaque have 
been linked to the regulation of signal transduction mechanisms 
that guide epithelial cell proliferation and differentiation (Balda 
and Matter, 2009). However, it is still poorly understood how 
junctional membrane proteins regulate these mechanisms and 
how they cross talk with the major signaling networks that guide 
cell behavior. Deregulation of expression of junctional trans-
membrane proteins has been reported for cancers, indicating 
that they may be important for tumorigenesis; however, it is not 
known whether up- or down-regulation is a consequence or cause 
of disease (Martin et al., 2011).
The three transmembrane proteins Occludin, Tricellulin, 
and MarvelD3 form the family of tight junction–associated 
Marvel domain proteins (Steed et al., 2010). Of the three, only 
MarvelD3 is a transmembrane component of tight junctions, but there is little evidence for a direct involvement in the junctional permeability bar-
rier. Tight junctions also regulate signaling mechanisms 
that guide cell proliferation; however, the transmembrane 
components that link the junction to such signaling path-
ways are not well understood. In this paper, we show 
that MarvelD3 is a dynamic junctional regulator of the 
MEKK1–c-Jun NH2-terminal kinase (JNK) pathway. Loss 
of MarvelD3 expression in differentiating Caco-2 cells 
resulted in increased cell migration and proliferation, 
whereas reexpression in a metastatic tumor cell line inhibited 
migration, proliferation, and in vivo tumor formation. 
Expression levels of MarvelD3 inversely correlated with 
JNK activity, as MarvelD3 recruited MEKK1 to junctions, 
leading to down-regulation of JNK phosphorylation and 
inhibition of JNK-regulated transcriptional mechanisms. 
Interplay between MarvelD3 internalization and JNK 
activation tuned activation of MEKK1 during osmotic 
stress, leading to junction dissociation and cell death in 
MarvelD3-depleted cells. MarvelD3 thus couples tight 
junctions to the MEKK1–JNK pathway to regulate cell be-
havior and survival.
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MarvelD3, which is resistant to the siRNAs used, indicating 
that the observed phenotype was specific (Fig. 1, F–H). These 
data indicate that depletion of MarvelD3 stimulates cell migra-
tion and proliferation of Caco-2 cells.
MarvelD3 has recently been shown to be down-regulated 
during snail-induced epithelial to mesenchymal transition in 
pancreatic epithelial cells (Kojima et al., 2011). Indeed, we found 
MarvelD3 expression to be strongly reduced in cell lines with 
invasive phenotypes derived from breast, pancreatic, and pros-
tate tumors (i.e., MDA-MB-231, PC3, and MiaPaca-2; Fig. 2, 
A and B).
As an additional control for the specificity of the siRNAs 
used, MiaPaca-2 cells, which do not express detectable MarvelD3 
protein, were transfected with the siRNAs, and the migration 
and proliferation experiments were repeated. Fig. S1 (A and B) 
shows that the siRNAs did indeed not affect the behavior of 
MiaPaca-2 cells. In contrast, in MCF7 cells, which express 
MarvelD3, depletion also stimulated migration and prolifera-
tion (Fig. S1, C–E).
To address the possibility that MarvelD3 can regulate cell 
behavior of invasive tumor cells, we expressed MarvelD3 in the 
pancreatic tumor cell line MiaPaca-2. Though there are two iso-
forms of MarvelD3, only isoform 1 could be detected in human 
pancreas by RT-PCR (Fig. 2 C; Steed et al., 2009). We therefore 
transfected MiaPaca-2 cells with a cDNA encoding isoform 
1 and isolated two clones expressing comparable levels of 
MarvelD3 isoform 1 mRNA as normal pancreas (Fig. 2 C). Both 
clones expressed similar amounts of MarvelD3 protein (Fig. 2 D). 
Phase-contrast microscopy revealed that MarvelD3-expressing 
cells were less spindle shaped than control MiaPaca-2 cells and 
that the transfected protein was enriched at cell–cell contacts 
(Fig. 2 E). However, MarvelD3 reexpression did not induce a 
reversal of the epithelial to mesenchymal transition. Though 
ZO-1 was occasionally seen at cell–cell contacts, crucial adhe-
sion proteins, such as E-cadherin and Occludin, were not re-
cruited to these contacts sites, and their expression remained the 
same or was reduced (Fig. S2, A and B).
We next performed migration assays to determine whether 
reexpression indeed led to a corresponding gain-of-function 
phenotype. For each cell line, RFP- and GFP-expressing cells 
were used to follow intermixing of cells once the wound was 
closed. Fig. 2 (F and G) shows that control cells closed the 
cell-free space more quickly than MarvelD3-expressing clones. 
When RFP- and GFP-expressing MiaPaca-2 cells were co- 
cultured, MarvelD3-expressing cells formed distinct islands of 
green and red cells, whereas control cells formed randomly 
mixed monolayers, indicating that cell mobility within mono-
layers was also reduced by expression of MarvelD3 (Fig. S2 C). 
Similarly, reexpression of MarvelD3 repressed proliferation of 
MiaPaca-2 cells (Fig. 2 H).
Finally, we xenografted MiaPaca-2 cell lines into nude 
mice to determine the propensity of MarvelD3 to suppress pro-
liferation in vivo. Control cells formed large tumors, and the 
tumor volume regularly increased until the end of the experi-
ment (Fig. 2, I and J). In contrast, clones expressing MarvelD3 
only formed very small tumors. MarvelD3 can thus suppress 
proliferation of tumor cells in vitro and in vivo. These data indicate 
Tricellulin seems to be directly required for the formation of 
functional paracellular diffusion barriers (Saitou et al., 2000; 
Ikenouchi et al., 2005; Krug et al., 2009; Steed et al., 2009; 
Raleigh et al., 2010). Hence, these proteins may be less impor-
tant for barrier formation but may regulate junctional signaling 
mechanisms. Indeed, Occludin manipulation affects the per-
meability properties of tight junctions in different tissues and 
experimental systems, which is compatible with Occludin func-
tioning as a regulatory protein (Balda et al., 1996; McCarthy 
et al., 1996; Chen et al., 1997; Hirase et al., 1997; Wong and 
Gumbiner, 1997; Antonetti et al., 1998, 1999; Matter and Balda, 
1998). MarvelD3 is less well understood but may also have a 
modulatory role (Steed et al., 2009; Kojima et al., 2011). Ex-
pression of all three junctional Marvel domain proteins can be 
deregulated in different cancers or cancer cell lines; however, 
the pathological significance of these observations is not clear 
(Martin et al., 2010; Kojima et al., 2011; Korompay et al., 2012). 
Nevertheless, Occludin has been shown to cross talk with onco-
genic Raf-1 signaling, as its expression is repressed by the ki-
nase, and it can suppress junction dissolution induced by Raf-1 
signaling if reexpressed ectopically (Li and Mrsny, 2000). The 
mechanism by which Occludin suppresses the effect of Raf-1 
on cell–cell junctions is not clear.
Here, we demonstrate that MarvelD3 functions as a regu-
lator of epithelial cell proliferation, migration, and survival. Our 
data show that MarvelD3 recruits MEKK1 to tight junctions to 
suppress the MEKK1–JNK pathway, leading to the suppression 
of JNK-regulated transcriptional mechanisms, inhibition of 
Cyclin D1 expression, and reduced cell proliferation and migra-
tion. We further show that interplay between dynamic MarvelD3 
behavior and JNK signaling is important for the cellular re-
sponse to osmotic stress.
Results
MarvelD3 regulates cell proliferation  
and migration
We first used a loss of function approach to ask whether MarvelD3 
regulates epithelial cell migration and proliferation. As a model 
system, we used Caco-2 cells, a human intestinal cell line that 
spontaneously differentiates, and depleted MarvelD3 expression 
using specific siRNAs.
MarvelD3-targeting siRNAs efficiently depleted expres-
sion of the protein as described (Fig. 1 A; Steed et al., 2009). 
Wound-healing assays were then performed with confluent 
monolayers. Bright-field microscopy and subsequent quantifi-
cations revealed an increased rate of gap closure in monolayers 
depleted of MarvelD3, covering almost twice the space as con-
trols in 26 h (Fig. 1, B and C). MarvelD3-depleted monolayers 
retained intact junctions, indicating that MarvelD3-depleted 
cells still migrated as cell sheets (Fig. 1 D). As the migration 
assays were performed in the presence of mitomycin C, en-
hanced wound closer was not caused by increased proliferation 
but faster migration. Nevertheless, proliferation assays indi-
cated that MarvelD3 depletion also resulted in elevated cell 
numbers (Fig. 1 E). The functional effects observed upon deple-
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that MarvelD3 specifically suppresses the JNK MAPK pathway 
(Fig. 3, A and B). Depletion of MarvelD3 in Caco-2 and MCF7 
cells led to increased phosphorylation of JNK (Figs. 3, C and D; 
and S2, D and E), providing further support for a role of 
MarvelD3 in the regulation of JNK activation.
JNK activates the AP1 transcription factor complex by 
phosphorylation of c-Jun, one of its subunits (Davis, 2000). 
Therefore, we measured AP1 activity using a luciferase reporter 
gene assay with an AP1-responsive promoter. Transfection of 
either MarvelD3 isoform repressed luciferase expression in 
Caco-2 and MiaPaca-2 cells, indicating that MarvelD3 can 
suppress AP1 activity in cells with and without tight junctions 
(Fig. 3, E–G). In contrast, transfection of Occludin did not 
affect AP1 activity, suggesting that inhibition is not a general 
effect of Marvel domain–containing proteins. As expected, 
that MarvelD3 regulates cell proliferation and cell migration of 
differentiating and dedifferentiated epithelial model cell lines, 
indicating that it functions as a signaling transmembrane com-
ponent of tight junctions.
MarvelD3 suppresses JNK signaling
The MAPK signaling pathways are fundamental for the regula-
tion of cell proliferation, migration, and survival. MAPKs are 
stimulated by kinase cascades that result in their phosphory-
lation. We therefore asked whether MarvelD3 expression af-
fects phosphorylation of MAPKs using the MiaPaca-2–derived 
MarvelD3-expressing cell lines. MarvelD3-expressing cells 
exhibited strongly reduced levels of phosphorylated JNK in 
comparison to control cells, whereas the levels of phosphory-
lated p38 and Erk1/2 were not significantly affected, indicating 
Figure 1. MarvelD3 regulates cell migration and proliferation in Caco-2 cells. (A–E) Caco-2 cells were transfected with siRNAs, and total cell extracts 
were analyzed by immunoblotting (A), or cells were assayed for migration or proliferation (B–E). B shows phase-contrast images, and D shows a maximal 
intensity projection of migrating cells labeled for tight and adherens junction proteins. The yellow lines label the wound edges at time 0. (C) Migration in 
to the cell-free space was measured after 26 h and normalized to controls. Shown are means ± 1 SD; n = 3. (E) Proliferation was analyzed by measuring 
the increase in cell numbers and normalizing the numbers to control cultures. Shown are means ± 1 SD; n = 3. (F–H) A complementation assay to test the 
specificity of MarvelD3 siRNAs was performed by repeating the assays as described in B–E using a Caco-2 cell line expressing mouse MarvelD3 (M-MD3) 
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cells confirmed the effect of MarvelD3 on cyclin D1 expression. 
MarvelD3 signaling thus regulates the expression of this central 
cell cycle regulator, providing a mechanistic explanation for its 
proliferation suppressive activity (Fig. 3, J and K).
We next asked whether JNK activity is indeed important 
for MarvelD3-regulated cell migration and proliferation. Inhi-
bition of JNK with the specific inhibitor SP600125 suppressed 
migration and proliferation of MiaPaca-2 cells, indicating that 
JNK signaling is indeed important for migration and prolifera-
tion of this tumor cell line (Fig. 4, A–C). Similarly, migration of 
MarvelD3-depleted Caco-2 cells was blocked by the JNK in-
hibitor (Fig. 4 D). The increase in cell numbers induced by 
MarvelD3 depletion was also strongly reduced by SP600125 
(Fig. 4 E). If JNK expression was suppressed with siRNAs 
targeting JNK1/2, stimulation of proliferation and migration by 
MarvelD3 expression also suppressed the activity of a serum 
response element (SRE)–driven promoter, in agreement with 
JNK’s regulatory role in Elk1 activation (Fig. 3 H; Cavigelli 
et al., 1995; Davis, 2000). ZO-1–associated nucleic acid bind-
ing protein (ZONAB) and T cell factor/-catenin represent tran-
scriptional pathways that are regulated by cell junctions, but 
their activities were not affected (Fig. 3 H).
To analyze the role of MarvelD3 in the regulation of physi-
ologically relevant promoters, we used a cyclin D1 promoter con-
struct (Watanabe et al., 1996; Sourisseau et al., 2006). The cyclin 
D1 promoter is regulated by multiple JNK-regulated transcrip-
tion factors (Klein and Assoian, 2008). Indeed, activity of the 
cyclin D1 promoter was reduced upon MarvelD3 expression and 
was stimulated upon its depletion (Fig. 3, H and I). Analysis of pro-
tein expression in transfected MiaPaca-2 and depleted Caco-2 
Figure 2. MarvelD3 regulates cell migration and proliferation of MiaPaca-2 cells. (A and B) Immunoblotting of extracts of cell lines derived from breast 
and pancreas (A) and prostate (B). (C) RT-PCR analysis of MarvelD3 isoform expression in healthy adult pancreas, and control and MarvelD3 isoform 1– 
transfected MiaPaca-2 cells. (D) Immunoblotting of control and MarvelD3 isoform 1–transfected MiaPaca-2 cells. (E) Morphology of control and MarvelD3-
expressing MiaPaca-2 cells (two clones, C2 and C8, were analyzed in all experiments) was assessed by phase-contrast and immunofluorescence 
microscopy (see Fig. S2 for analysis of other junctional markers). (F and G) Migration assays were performed with GFP- and RFP-expressing pools of control 
and MarvelD3-expressing MiaPaca-2 cells over 2 d. The quantification was performed, and images were taken after 24 h and show means ± 1 SD; n = 3. 
Note, only control cells freely mix after they have filled the gap or when labeled cells are co-cultured (see Fig. S2 C for co-cultures). (H) Proliferation of 
control and MarvelD3-expressing cells was analyzed by measuring cell numbers after 3 d (shown are means ± 1 SD; n = 3). (I and J) Nude mice were in-
jected with control or MarvelD3-expressing MiaPaca-2 cells, and tumor formation was assessed by measuring the size over 47 d. Shown are means ± 1 SD 
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two isoforms had comparable effects on the activity of tran-
scriptional reporter constructs, we speculated that this N-terminal 
domain is responsible for the signaling activity. In support of 
this hypothesis, repetition of the AP1 reporter assay with con-
structs containing only the N-terminal domain (MarvelD3_NTD) 
or lacking it (MarvelD3_1NTD) demonstrated that the N-terminal 
cytoplasmic domain was both necessary and sufficient to regu-
late AP1 activity (Fig. 5 A).
We next tested whether the N-terminal cytoplasmic do-
main interacts with upstream components that regulate JNK 
MarvelD3 suppression was also inhibited, indicating that 
MarvelD3 is indeed acting on JNK (Fig. 4, F–H). Inhibition of 
JNK also inhibited increased expression of cyclin D1, indicat-
ing that regulation of expression of the cell cycle gene by 
MarvelD3 involves the JNK pathway (Fig. 4, I and J).
The N-terminal cytoplasmic domain 
regulates signaling
MarvelD3 is expressed as two isoforms with a common 
N-terminal cytoplasmic domain (Steed et al., 2009). As the 
Figure 3. MarvelD3 regulates JNK signaling and cyclin D1 expression. (A and B) Control and MarvelD3-expressing MiaPaca-2 cells were analyzed by immuno-
blotting of whole-cell lysates to monitor phosphorylation of MAPKs. B shows a quantification of the ratios between phosphorylated and nonphosphorylated 
forms. (C and D) Caco-2 cells transfected with control and MarvelD3-targeting siRNAs were analyzed for MAPK activation as described in A and B. (E and F) Analysis 
of AP1 promoter activity using a dual-luciferase reporter assay in Caco-2 (E) and MiaPaca-2 (F) cells. Control cells were cotransfected with an empty expression 
vector, and the other cells were cotransfected as indicated with cDNAs encoding MarvelD3 isoforms or Occludin. (G) Immunoblot of Caco-2 cells transfected 
as in E using antibodies against MarvelD3 and Occludin. (H) Activities of the indicated promoters were analyzed as in E and F. (I–K) Analysis of cyclin D1 
expression was analyzed by reporter gene assay in control and MarvelD3-targeting siRNA-transfected Caco-2 cells or by immunoblotting in MiaPaca-2 and 
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such as ZO-1, -2, and -3, were also not detected in the pull-downs 
(Fig. 5 B). Reconstitution experiments with recombinant proteins 
indicated that the interaction between the N-terminal domain of 
MarvelD3 and MEKK1 can occur directly and involves the kinase 
domain (Fig. 5, C and D).
To confirm the relevance of this in vitro interaction, we 
tested whether MarvelD3 affects the subcellular distribution of 
MEKK1 using control and MarvelD3-expressing MiaPaca-2 
cells. Fig. 5 E shows that MEKK1 was indeed partially recruited to 
activation. We first performed GST pull-down assays from whole 
Caco-2 cell lysates using fusion proteins containing the cyto-
solic domains of MarvelD3 (NTD [N-terminal domain], CTD1 
[C terminus of isoform 1], and CTD2 [C terminus of isoform 2]). 
Subsequent blotting with antibodies against MAPKKKs re-
vealed that MEKK1 was pulled down specifically by the fusion 
protein containing the N-terminal domain. Other MAPKKKs, 
such as MEKK3 and MLK1, which can also signal to JNK, 
were not detected. Prominent junctional scaffolding proteins, 
Figure 4. JNK signaling and regulation of proliferation and migration. (A) MiaPaca-2 cells were incubated with 20 and 50 µM SP600125, and JNK 
inhibition was then analyzed by blotting for phosphorylated c-Jun. All subsequent experiments were performed with 20 µm SP600125. (B–E) Migration and 
proliferation of MiaPaca-2 (B and C) and siRNA-transfected Caco-2 cells (D and E) were analyzed as in Fig. 1. No increase in cell death was observed 
when similarly treated cells were analyzed by DNA staining (Fig. 9). (F–H) Caco-2 cells were transfected with control and MarvelD3- and JNK1/2-targeting 
siRNAs as indicated. After 3 d, the cells were analyzed by immunoblotting (F), for cell migration (G), or cell proliferation (H). (I and J) Control and MarvelD3 
siRNA–transfected Caco-2 cells were incubated with DMSO or SP600125 for 10 h before lysis and analysis by immunoblotting. J shows a quantification of 
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Figure 5. MarvelD3 regulates MEKK1 localization. (A) AP1 reporter gene assays were performed with MarvelD3 constructs consisting of the N-terminal 
domain only (MarvelD3_NTD) or lacking this domain (MarvelD3_1NTD). Shown are means ± 1 SD; n = 3. (B) GST pull-down assays were performed 
using Caco-2 cell extracts and fusion proteins containing either the N-terminal domain (GST-MarvelD3_NTD) or either one of the two isoform C-terminal do-
mains (GST-MarvelD3_CTD1 and GST-MarvelD3_CTD2). The precipitates were then analyzed by immunoblotting as indicated. (C) Schematic of MEKK1. 
Indicated are the RING finger and the kinase domains as well as the regions contained by the fusion proteins used for the recombinant protein-binding 
assay in D. IR, intervening region. (D). His6-tagged MEKK1 fusion proteins were incubated with GST-MarvelD3_NTD fusion protein bound to glutathione 
beads. After washing, bound fusion proteins were eluted analyzed by immunoblotting using antibodies against His6 and GST. (E) Control and MarvelD3-
expressing MiaPaca-2 cells were stained for the VSV-tagged transfected protein and MEKK1. Arrowheads point to cell–cell contacts positive for MEKK1. 
(F and G) Immunoblotting of Caco-2 cells transfected with siRNAs as indicated. (H and I) Caco-2 cells transfected with the indicated siRNAs were stained 
with mouse anti-MEKK1 and rabbit anti-MarvelD3 antibodies. Arrowheads point to junctional fragments positive for MEKK1. Graphs in I show ratios of 
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streptavidin precipitates with anti-MEKK1 antibodies demon-
strated that the kinase was biotinylated in both types of cell 
lines (Fig. 6 D). Despite the lower levels, the fusion protein car-
rying the biotin ligase on the N terminus biotinylated MEKK1 
more efficiently. Moreover, in transiently transfected Caco-2 cells, 
biotinylation of MEKK1 was only observed with the N-terminal 
fusion protein, possibly because of the low transfection effi-
ciency of such cells (Fig. 6 E). These data thus support a model 
in which complex formation between MarvelD3 and MEKK1 
involves the N-terminal cytoplasmic domain of the tight junc-
tion protein.
Our data thus indicate that MarvelD3 regulates the sub-
cellular distribution of MEKK1. As MarvelD3 also suppresses 
JNK activation and its N terminus is sufficient and required to 
suppress AP1 activity, regulation of a MEKK1–JNK pathway 
seems a major mechanism by which MarvelD3 regulates epi-
thelial cell behavior.
MarvelD3 is required for epithelial integrity 
during osmotic stress
To further address the significance of this mechanism, we inves-
tigated the osmotic shock response, in which JNK plays a cru-
cial role (Seki et al., 2012). Strikingly, the subcellular distribution 
of MarvelD3 drastically changed in response to osmotic stress. 
Fig. 7 A shows that MarvelD3 was quickly internalized and, 
after an initial distribution in scattered vesicular structures, 
started to accumulate in perinuclear endosome-like structures 
before reappearing at the cell surface and cell–cell junctions. 
cell–cell contacts when MarvelD3 was expressed in MiaPaca-2 
cells but not in control cells, indicating that reexpression of the 
junctional membrane protein is sufficient to stimulate membrane 
recruitment of MEKK1. Similarly, MEKK1 antibodies stained 
cell junctions in control Caco-2 cells but not when MarvelD3 
had been depleted (Fig. 5, F–I). In contrast, depletion of MEKK1 
did not affect the distribution of the junctional membrane pro-
tein. MarvelD3 thus regulates the localization of MEKK1.
Our data indicate that MEKK1 can form complexes in vitro 
with MarvelD3 and that its subcellular distribution is regulated 
by the junctional membrane protein. However, we were un-
able to reliably coimmunoprecipitate MarvelD3 and MEKK1. 
Therefore, we made use of a recently published strategy to iden-
tify proteins in close proximity in live cells, which relies on a pro-
miscuous biotin ligase that is fused to the protein of interest to 
transfer biotin to nearby lysine residues (Roux et al., 2012). We 
generated two MarvelD3 fusion proteins that carried the biotin 
ligase either at the N (Myc-BirA-MarvelD3) or the C terminus 
(MarvelD3-BirA-HA) and stably expressed them in MDCK 
cells. Both fusion proteins were efficiently expressed and trans-
ported to cell–cell contacts (Fig. 6, A–C). When biotin had been 
added to the cultures before fixation, a strong streptavidin stain-
ing was obtained in cells expressing the chimeric proteins but 
not in neighboring cells that lacked expression (Fig. 6, A and B). 
MarvelD3/biotin ligase chimeras are thus targeted to cell junc-
tions and can mediate biotinylation of cellular proteins.
We then extracted whole-cell lysate and isolated biotinylated 
proteins with streptavidin immobilized on beads. Immunoblotting 
Figure 6. MarvelD3 and MEKK1 form complexes. (A and B) MDCK cell lines expressing MarvelD3 fusion proteins carrying the biotin ligase at the 
C terminus (A) or the N terminus (B) were incubated with biotin for 24 h as indicated before fixation and staining with fluorescently labeled streptavidin and 
anti-HA (A) or anti-Myc antibodies. The white lines demark the border between cells that do and do not express the fusion protein. (C) Immunoblotting of 
extracts of cells expressing the MarvelD3 biotin ligase fusion proteins. (D) Cell extracts of the cell lines shown in A and B were incubated with streptavidin 
beads, and the resulting precipitates were blotted with the indicated antibodies. (E) Caco-2 cells transiently transfected as indicated were analyzed as 
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Figure 7. MarvelD3 is required for epithelial monolayer integrity during osmotic stress. (A and B) Caco-2 cells were osmotically stressed for the times 
indicated before analysis by immunofluorescence (A) or immunoblotting (B). The insets in A show twofold magnifications of the MarvelD3 staining. 
(C–H) Cells were transfected with control and MarvelD3 targeting siRNAs and were then osmotically stressed. The cells were then analyzed by immunoblotting (C), 
immunofluorescence (D–G), or by measuring electrical impedance (H). Cells were stained for Occludin and MarvelD3 (D), ZO-1 (E), or F-actin (G). For a 
quantification of Occludin and MarvelD3 localization and comparison with endocytic markers, see Fig. S3. F shows a quantification of the area covered 
by individual cells to assess cell contraction. Shown are means ± 1 SD of three experiments counting 20–40 cells per condition and experiment; ***, P < 
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been depleted and remained about twofold higher during the 
entire time course (Fig. 8, A–C). Increased phosphorylation of 
JNK was also evident when cells were analyzed by immuno-
fluorescence (Fig. 8 D). MEKK1 was also affected. Upon ap-
plication of an osmotic shock, the kinase dispersed before 
accumulating again at junctions at later time points (Fig. 8 E; a 
different fixation method was used compared with Fig. 5 H, 
which reduced the cytoplasmic background but increased non-
specific nuclear staining; Fig. S4, control siRNA experiments 
and quantification of MEKK1 distribution). Phosphorylation of 
MEKK1 was induced with similar kinetics in control and de-
pleted cells, but again, phosphorylation was more intense and 
sustained in depleted cells (Fig. 8, F and G). The kinetics of ac-
tivation and inactivation of p38 and Erk1/2 were not affected by 
MarvelD3 depletion (Fig. S5, A and B). These results further 
support the conclusion that MarvelD3 modulates the MEKK1–
JNK pathway and not Erk1/2 and p38 signaling.
MEKK1 does not only induce activation of JNK and 
phosphorylation of c-Jun, it can also stimulate c-Jun degrada-
tion (Xia et al., 2007). Figs. 8 H and S5 C show that there was a 
modest increase in phosphorylation of c-Jun before osmotic 
shock despite lower total expression levels in MarvelD3- 
depleted cells. In control cells, osmotic shock caused an increase 
in phosphorylated c-Jun levels. However, if compared with the 
total expression level of c-Jun, phosphorylation remained 
higher in MarvelD3-depleted cells (Fig. S5 C). Reduced ex-
pression of c-Jun in MarvelD3-depleted cells only affected 
protein expression and was not observed at the mRNA level 
(Fig. S5, D and E) and was paralleled by a decrease in c-Jun 
protein stability (Fig. S5, F and G), suggesting that MarvelD3 
depletion indeed led to increased MEKK1-stimulated c-Jun 
degradation. As we had observed that MarvelD3 also regulates 
the SRE promoter, we next asked whether MarvelD3 depletion 
also affected phosphorylation of Elk1, which can also be acti-
vated by JNK (Cavigelli et al., 1995; Davis, 2000). Indeed, Elk1 
phosphorylation was also enhanced in MarvelD3-depleted cells 
in response to hyperosmotic shock, further supporting the con-
clusion that MarvelD3 depletion led to enhanced MEKK1–JNK 
signaling (Fig. 8, I and J).
Prolonged activation of MEKK1–JNK signaling and deg-
radation of c-Jun leads to cell death (Xia et al., 2007; Seki et al., 
2012); hence, we stained nuclei in osmotically stressed cells 
and quantified fragmented nuclei and apoptotic bodies, hall-
marks of apoptosis. Fig. 9 A shows that fragmented nuclei were 
more commonly observed in MarvelD3-depleted than in control 
cells. Quantification confirmed this increase in fragmented 
nuclei (Fig. 9 B). Measurements of caspase 3/7 activity and 
TUNEL assays confirmed that MarvelD3 depletion indeed 
stimulated apoptosis in response to osmotic shock (Fig. 9, C–E). 
MarvelD3-mediated attenuation of MEKK1–JNK signaling is 
thus crucial for cell survival during osmotic stress.
JNK stimulates MarvelD3 internalization
Our data indicate that MarvelD3 expression at the cell surface 
is important for the attenuation of MEKK1–JNK signaling. 
Therefore, we asked whether initial MAPK stimulation trig-
gers MarvelD3 internalization.
There was no apparent reduction in MarvelD3 expression during 
this time course even when protein synthesis was blocked with 
cycloheximide, suggesting that internalized protein did not get 
degraded but recycled (Figs. 7 B and S3 A). The perinuclear 
pool of MarvelD3 partially overlapped with transferrin recep-
tor, suggesting that trafficking involved an endocytic recycling 
route (Fig. S3, B–D). In contrast, Occludin was more stably as-
sociated with the junctions and no endocytic burst was observed, 
but the staining became warped, irregular, and occasionally dis-
continuous (Fig. 7 A). Only after long osmotic shock times (>2 h), 
when MarvelD3 already started to reappear at the cell surface, a 
modest increase in perinuclear vesicular Occludin staining was 
evident (Figs. 7 A and S3 E). Thus, the junctional association of 
MarvelD3 is regulated by osmotic stress.
We next asked whether MarvelD3 is important for the cel-
lular response to osmotic stress by making use of siRNAs to de-
plete its expression (Fig. 7 C). Repetition of the osmotic stress 
treatments followed by immunofluorescence for Occludin and 
ZO-1 revealed that MarvelD3 was indeed important for mainte-
nance of the molecular junctional structure during the osmotic 
stress response, as the distribution of ZO-1 and, to a lesser ex-
tent, Occludin started to become discontinuous within 2 h in the 
absence of MarvelD3 (Figs. 7, D and E; and S3 F). Moreover, 
the surface area rapidly reduced in control cells in response 
to osmotic shock but not when MarvelD3 had been depleted 
(Fig. 7 F). These morphological changes were even more evi-
dent when cells were stained for F-actin, as the depleted cells 
became more spread and lost their normally regular cell shape 
(Fig. 7 G). Control cells reassembled a reinforced junctional 
F-actin ring after 480 min of osmotic treatment, but MarvelD3-
depleted cells failed to do so. Instead, the F-actin network became 
increasingly disorganized. MarvelD3 is thus important for the 
maintenance of the junctional structure during osmotic stress.
MarvelD3 depletion does not affect epithelial barrier in-
tegrity in steady-state Caco-2 monolayers (Steed et al., 2009; 
Raleigh et al., 2010). Hence, we determined whether its depletion 
affected epithelial barrier integrity under stress. Transepithelial 
electrical impedance measurements showed that both control 
and MarvelD3-depleted cells responded with a rapid drop in elec-
trical impedance when the osmotic shock was applied (Fig. 7 H). 
Control cells then started to recover, and impedance slowly 
increased again. However, impedance of MarvelD3-depleted 
monolayers continued to decrease and did not recover, indicat-
ing that the epithelial barrier was defective. MarvelD3 is thus 
required for epithelial barrier integrity during osmotic stress.
MarvelD3 regulates cell survival during 
osmotic stress
Because JNK signaling is an important component of the cellu-
lar stress response (Xia et al., 2007; Seki et al., 2012), we next 
asked whether MarvelD3 regulates JNK signaling during osmotic 
stress. To do so, we analyzed the activation profile of JNK in 
response to osmotic shock.
Levels of phosphorylated JNK increased within the first 
hour of hyperosmotic shock independent of whether control or 
MarvelD3-depleted cells were analyzed; however, phosphory-
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Figure 8. MarvelD3 and the MEKK1–JNK pathway during osmotic stress. (A–J) Caco-2 cells were transfected with control and MarvelD3 siRNAs and 
were then osmotically stressed for the times indicated before analysis by immunoblotting (A–C and F–J), staining for phospho-Jnk (p-JNK; D) or with mouse 
anti-MEKK1 antibodies (E). Arrowheads in E mark cell–cell contacts positive for MEKK1. The graphs in C, G, and J show individual determinations, and 
the lines were drawn through the corresponding means for each time point. See Fig. S4 for specificity controls for the MEKK1 staining and quantification 
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of MarvelD3-depleted cells. These data thus indicate that inter-
play between JNK signaling and MarvelD3 regulates epithelial 
integrity and cell survival.
Discussion
To maintain tissue integrity and function, cells need to be able 
to respond to changes in their environment in a controlled man-
ner. Here, we report the discovery of a new mechanism that 
links cell–cell adhesion to the regulation of cell proliferation 
and migration and that controls signaling in response to osmotic 
stress to ensure cell survival and epithelial integrity. Our data 
indicate that MarvelD3 links tight junctions to the control of 
the MEKK1–JNK pathway to guide the extent and duration of 
pathway activation and that this mechanism is important for the 
regulation of cell behavior.
Manipulation of MarvelD3 strongly affected cell migra-
tion and proliferation. MEKK1 and the JNK pathway are well-
known regulators of migration (Xia et al., 2000; Yujiri et al., 
2000). Similarly, MEKK1 and JNK signaling stimulate the tran-
scription factors AP1 and Elk1, and their transcriptional activities 
were regulated by MarvelD3. AP1 and Elk1 promote expression 
of genes that stimulate proliferation, such as cyclin D1 (Cavigelli 
et al., 1995; Davis, 2000). Expression of cyclin D1 was strongly 
Fig. 10 A shows that inhibitors of extracellular signal–
regulated kinase (Erk; UO126) and p38 (SB202190) did not 
affect internalization. However, the JNK inhibitor SP600125 
prevented internalization, and MarvelD3 remained concentrated 
at cell–cell contacts (Fig. 10, A and B). Inhibitors of src tyrosine 
kinases had no effect on MarvelD3 redistribution. These data 
thus indicate that the initial JNK activity is important for stimu-
lation of MarvelD3 internalization.
To test whether JNK activation is indeed important for the 
epithelial response to osmotic stress, we tested how inhibition 
of the kinase affects cell behavior. Fig. 10 C shows that inhibi-
tion of JNK not only prevented MarvelD3 internalization but 
also cell contraction. With increasing times of stress, the cells 
were not only more spread, but junctional staining started to 
become discontinuous when JNK was inhibited and the cells 
started to die, indicating that activation of JNK signaling during 
stress is functionally important (Figs. 10 D and S5 H). However, 
when the inhibitor was added only 15 min after the shock had 
been applied, no significant increase in cell death was observed 
and junction dissociation was attenuated (Figs. 10 E and S5 I). 
If this delayed addition of the JNK inhibitor was repeated with 
MarvelD3-depleted cells, it strongly attenuated cell death and 
junction dissociation (Figs. 10 E and S5 I). Hence, inhibition of 
prolonged JNK signaling rescued the stress-induced phenotype 
Figure 9. MarvelD3 depletion induces apoptosis during osmotic stress. (A–E) Caco-2 cells were transfected with siRNAs and then osmotically stressed 
as indicated. The cells were then either labeled by nuclear staining (A and B), for determination of caspase 3/7 activation (C), or using a TUNEL assay 
(D and E). B shows a quantification of nuclear fragmentation as an indication of apoptotic cells. C shows a quantification of caspase 3/7 induction. E shows 
cells fluorescently labeled in the TUNEL assay. All graphs show means ± 1 SD; n = 3 (B), n = 5 (C), and n = 8 (E). *, P < 0.05; **, P < 0.01; ***, P < 
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Figure 10. Regulation of MarvelD3 internalization by JNK. (A and B) Caco-2 cells were preincubated with the indicated inhibitors before a 15-min 
osmotic shock under the same condition. The cells were then fixed and stained for MarvelD3. B shows a quantification of junction-associated MarvelD3 fluor-
escence; provided are means ± 1 SD; n = 8. Note, only the JNK inhibitor SP600125 prevents MarvelD3 internalization. (C) Cell contraction was assessed 
as described in Fig. 6 F. Shown are means ± 1 SD of three experiments counting 20–40 cells per condition and experiment. (D) Cells were preincubated 
with the JNK inhibitor SP600125 or DMSO (control) and then osmotically stressed under the same conditions for 8 h before fixation and staining for 
the junctional markers ZO-1 and p120Catenin. (E) Cells transfected with the indicated siRNAs were hyperosmotically shocked for 8 h. The JNK inhibitor 
SP600125 was added either together with the hypertonic medium or 15 min after shock induction. Apoptosis was then assessed with a TUNEL assay. 
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experiments, however, depletion of MarvelD3 can also lead to 
barrier failure caused by cell death and junction dissociation. 
Hence, the experimental conditions under which such experi-
ments are performed and the type of model systems used can 
dramatically affect the results and may explain the variations 
observed in different studies on the role of MarvelD3 in junc-
tion formation (Steed et al., 2009; Raleigh et al., 2010; Kojima 
et al., 2011).
Another prominent example of this group of tight junction 
transmembrane proteins is Occludin (Furuse et al., 1993). Oc-
cludin does also not play a major structural role but functions 
as a regulator (Balda et al., 1996; McCarthy et al., 1996; Chen 
et al., 1997; Wong and Gumbiner, 1997; Antonetti et al., 1998, 
1999; Matter and Balda, 1998; Saitou et al., 1998, 2000). Occlu-
din and MarvelD3 are both Marvel domain proteins (Sánchez-
Pulido et al., 2002; Steed et al., 2009; Raleigh et al., 2010), and 
they have some similarities in their biological function and be-
havior. Occludin has been shown to cross talk with the Raf-1– 
Erk signaling cascade (Li and Mrsny, 2000; Wang et al., 2005). 
Hence, MarvelD3 and Occludin both functionally interact with 
MAPK signaling; however, they do so in fundamentally differ-
ent ways. Occludin performs a role downstream of Erk, as it 
does not affect activity of Erk but counteracts junction dissocia-
tion induced by oncogenic Raf-1 (Li and Mrsny, 2000; Wang 
et al., 2007). Hence, Occludin links the Raf-1–Erk pathway to 
junction regulation, whereas MarvelD3 links the junction to 
regulation of MEKK1–JNK signaling.
Another similarity between Occludin and MarvelD3 is 
that both are regulated by membrane traffic. Occludin is inter-
nalized via a caveolin-1–based mechanism in response to TNF 
signaling (Marchiando et al., 2010). MarvelD3 internalization 
is triggered by osmotic stress and requires JNK signaling. After 
initial internalization, MarvelD3 then recycles to the cell sur-
face and becomes again concentrated at tight junctions. The 
mechanisms underlying internalization and recycling remain to 
be identified. However, the dependence on JNK activity for in-
ternalization indicates that MarvelD3 recycling functions as a 
regulatory feedback mechanism: initial removal from the cell 
surface allows efficient activation of the MEKK1–JNK pathway 
followed by inhibition upon reappearance and accumulation at 
tight junctions. Both steps seem to be important for the epithe-
lial stress response, as inhibition of JNK not only inhibited 
MarvelD3 internalization but also led to increased cell death, 
whereas MarvelD3 depletion led to prolonged JNK signaling 
and increased cell death, and this could be rescued by inhibiting 
JNK after the initial 15 min of hypertonic stress. MarvelD3 thus 
functions as a negative regulator that tunes JNK signaling.
In this study, we demonstrate that MarvelD3 links tight 
junctions to the MEKK1–JNK pathway and exerts a negative 
feedback activity on the MAPK pathway that regulates cell 
proliferation, migration, and survival. The signaling activity of 
MarvelD3 may also be relevant in disease. Given the effect of 
MarvelD3 on cell migration and proliferation, it may have 
tumor suppressor activity. However, MEKK1 has recently been 
suggested to function as a tumor suppressor in breast cancer 
(Banerji et al., 2012; Cancer Genome Atlas Network, 2012; 
Ellis et al., 2012). An active MEKK1–JNK pathway may thus 
affected by MarvelD3 expression and followed the effect on the 
cyclin D1 gene promoter, indicating that cyclin D1 is indeed a 
target of MarvelD3 signaling. Increased migration and prolifer-
ation induced by MarvelD3 depletion were dependent on JNK 
signaling; hence, the JNK pathway is an important route by 
which MarvelD3 regulates cell behavior.
MarvelD3 inhibits JNK signaling by regulating the local-
ization of the upstream kinase MEKK1. Our data suggest that 
MarvelD3 inhibits the MAPK pathway by sequestration of the 
MAPKKK. In vitro, the N-terminal domain of MarvelD3 pulled 
down MEKK1 from cell extracts and interacted with the kinase 
domain in reconstitution experiments with recombinant proteins. 
Hence, junctional sequestration may involve formation of 
MarvelD3–MEKK1 complexes. However, we have not been able 
to coimmunoprecipitate MarvelD3 and MEKK1 from cell extracts, 
despite the biotinylation assay indicating that MEKK1 localizes 
in close proximity of MarvelD3. The reasons for this are not 
clear but may have sterical reasons, as the MarvelD3 antibodies 
had been generated against the N-terminal domain, which also 
binds MEKK1; unfortunately, the MEKK1 antibodies we tested 
immunoprecipitated the kinase only poorly or not at all. Alter-
natively, the interaction may not be stable as a result of its bio-
chemical and/or functional properties. It is possible that the role 
of the interaction between MEKK1 and MarvelD3 is a regulatory 
one. MEKK1 has previously been shown to bind to -actinin, 
and -actinin isoforms localize to tight and adherens junctions 
(Christerson et al., 1999; Patrie et al., 2002). Hence, MEKK1 
might be anchored to the junction by binding to -actinin, and 
MarvelD3 might regulate kinase activation and dissociation 
from the junction.
A model in which MarvelD3 regulates junctional localiza-
tion and, thereby, inactivation of MEKK1, is also supported by 
the osmotic shock experiments, as MarvelD3 was internalized 
and MEKK1 became dispersed. Whether removal of MarvelD3 
from junctions by osmotic stress or siRNA-mediated depletion 
is the only factor that contributed to the release of MEKK1 is 
not known. MEKK1 is activated by RhoA signaling, which is 
stimulated by growth factors and osmotic shock; hence, it may 
also be involved in the release of MEKK1 from tight junctions 
(Gallagher et al., 2004).
Depletion of MarvelD3 not only affected JNK activa-
tion but also c-Jun expression levels. MEKK1 can function as 
a ubiquitin ligase that stimulates the degradation of c-Jun (Xia 
et al., 2007). Hence, the decreased levels of c-Jun in MarvelD3-
depleted cells are likely to be caused by deregulation of MEKK1. 
Both c-Jun degradation and deregulation of JNK can induce cell 
death (Davis, 2000; Seki et al., 2012). It is thus likely that the 
combined action of these two mechanisms caused the increase 
in apoptosis that we observed in MarvelD3-depleted cells in 
response to osmotic stress.
MarvelD3 belongs to a growing family of tight junction 
proteins that do not seem to play a fundamental structural role 
in forming the junctional diffusion barrier (Steed et al., 2009; 
Raleigh et al., 2010). Together with the data presented here, this 
suggests that the main function of MarvelD3 is a regulatory 
one, transmitting signals from the junction to the cell interior to 
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temperature of 63°C using primers previously described (Steed et al., 
2009). The following primers were used to detect expression of human 
MarvelD3 isoforms: 5-AAAAATCTAGATCAAAGAGTTCCAGACCACAG-3 
and 5-AAAAATCTAGATTAAAATTCAAACATTTCTGCTGG-3 for reverse 
transcription and 5-AAAAAGCTAGCAAATACTTGTGCACTGGGAGAG-3, 
5-AAAAAGCTAGCTCGGTAGCTACGCAGGGC-3, and 5-AAAAAG-
CTAGCTCGGTAGCCCTTTATGGCCA-3 for PCR. For the detection of 
c-Jun mRNA expression, total RNA was reverse transcribed with the primer 
5-TCAAAATGTTTGCAACTGCTGCG-3, and a 676-bp fragment was am-
plified with the primer pair 5-CGTTAGCATGAGTTGGCACCCACTG-3 
and 5-CAAGAACGTGACAGATGAGCAGGAGG-3. For quantitative PCR, 
the latter primer was replaced by 5-AGCAGCAGCAGCAGCCGCCG-
CACCACC-3, and reactions were performed using Power SYBR Green 
PCR Master Mix and a thermal cycler (7900HT; Applied Biosystems; Nie 
et al., 2012).
Antibodies
A rabbit anti-MarvelD3 antibody was generated against the complete 
N terminus of MarvelD3 (amino acids 1–198; Steed et al., 2009). The rab-
bit anti–phospho-MEKK1 antibody was generated against a phosphory-
lated peptide containing serine 1436 of mouse MEKK1 (serine 1455 of 
human MEKK1), which had previously been shown to become phosphory-
lated in T cells upon T cell receptor stimulation, and was generated and pu-
rified as previously described (Gallagher et al., 2002; Enzler et al., 2009). 
Antibodies against other proteins were as previously described or were 
obtained from commercial sources: rabbit anti-MEKK1 (Abcam); mouse 
anti-pJNK, rabbit anti-JNK, mouse anti-pErk, rabbit anti-Erk, and rabbit 
anti-pp38 and -p38 (Cell Signaling Technology); goat anti-p120Catenin, 
mouse anti-pELK1, rabbit anti-ELK1, mouse anti-MEKK1, and goat anti-MEKK3 
and anti-MLK1 (Santa Cruz Biotechnology, Inc.); rabbit anti–cyclin D1 (MBL 
International); mouse anti-His6 (Sigma-Aldrich); mouse anti-Occludin and –
ZO-1 (Life Technologies); mouse anti-EEA1 (BD); mouse anti–-tubulin (anti-
gen: a peptide containing the last 11 C-terminal amino acids of porcine 
-tubulin) and mouse anti–-VSV (antigen: the peptide N-CGYTDIEMN-
RLGK-C; Kreis and Lodish, 1986; Kreis, 1987); rabbit anti–ZO-1 (anti-
gen: the peptide N-YTDQELDETLNDEVC-C), –ZO-2 (antigen: the peptide 
N-KMEGMDDDPEDRMSC-C), and –ZO-3 (antigen: the peptide N-CSD-
EDGYDWGPATDL-C; Benais-Pont et al., 2003); rabbit anti-GST (antigen: 
purified recombinant GST; Kavanagh et al., 2006); and mouse anti–transferrin 
receptor (antigen: isolated Golgi-enriched membranes from Caco-2 cells) 
and mouse anti-LAMP1 (antigen: isolated Golgi-enriched membranes from 
Caco-2 cells; Schweizer et al., 1988). Phalloidin was used to visualize 
F-actin. All secondary antibodies and fluorescently labeled streptavidin were 
obtained from Jackson ImmunoResearch Laboratories, Inc.
Immunofluorescence
Caco-2 or MiaPaca-2 cells were grown on glass coverslips for 3 d and 
then processed for immunofluorescence. Cells were fixed directly in metha-
nol at 20°C for 10 min or with 3% paraformaldehyde for 20 min fol-
lowed by permeabilization with 0.3% Triton X-100 as previously described 
(Matter and Balda, 2003; Steed et al., 2009). For the localization of 
EEA1, cells were fixed with 1% paraformaldehyde and for transferrin re-
ceptor with 1% paraformaldehyde followed by methanol before extracting 
for 10 min with 0.3% Triton X-100. Cells were then washed with PBS and 
blocked for 15 min with PBS containing 0.5% BSA (PBS-BSA) at room tem-
perature. Coverslips were incubated with primary antibodies overnight, 
washed three times with PBS-BSA, and incubated with secondary antibody 
and Hoechst nuclear stain at room temperature. Coverslips were washed 
twice more with PBS-BSA and once in PBS before being mounted with 
mounting medium (ProLong Gold; Invitrogen) and stored at 4°C. Epifluores-
cent images were collected at ambient temperature with a fluorescent 
microscope (DMIRB; Leica) using a Apochromat 63×, 1.4 NA oil immersion 
objective fitted with a camera (C4742-95; Hamamatsu Photonics) and Sim-
plePCI software (Hamamatsu Photonics) or an inverted microscope (Eclipse 
Ti-E; Nikon) using an Apochromat 60×,1.4 NA oil immersion objective, a 
camera (CoolSNAP HQ2; Photometrics), and Nikon software. Brightness 
and contrast were adjusted with Photoshop CS4 software (Adobe). ImageJ 
(National Institutes of Health) was used for quantifications of cell areas and 
fluorescent densities.
Immunoblotting
Whole-cell lysates were harvested by adding SDS sample buffer (3% SDS, 
15% glycerol, 0.0015% bromophenol blue, and 0.25 M Tris HCl contain-
ing 150 mM DTT and 8 M urea) to samples washed once with PBS. Sam-
ples were homogenized through a 25-gauge needle and, after a 30-min 
incubation at room temperature, analyzed by SDS-PAGE. Proteins were 
be beneficial for patients as tumor cells might die as a result of 
prolonged JNK signaling; hence, MarvelD3 expression may 
promote tumor cell survival by inhibiting MEKK1–JNK signal-
ing. The role of the MarvelD3–MEKK1–JNK pathway and how 
it affects tumorigenesis and disease progression may thus de-
pend on the type of tumor and the tumor microenvironment.
Materials and methods
Cell culture
Caco-2, MiaPaca-2, and MCF7 cells were grown in DMEM (Invitrogen) 
supplemented with 20% FBS (Invitrogen) for Caco-2 and 10% FBS for 
MiaPaca-2 and MCF7 cells. All cell lines were grown in the presence of 
100 U/ml penicillin and 100 µg/ml streptomycin (Invitrogen) at 37°C in a 
5% CO2 atmosphere. For hyperosmotic shock treatments, the medium was 
brought to 600 mOsm using NaCl.
siRNAs, cDNAs, and RT-PCR
For knockdown experiments, Caco-2 cells were transfected with individual 
or a pool of MarvelD3-specific siRNAs (Thermo Fisher Scientific) that were 
5-GAGAGGAGGTGGAATATTA-3 and 5-GCCGCAGACCCGAAAGTGA-3 
as previously described (Steed et al., 2009). MEKK1 was targeted with the 
following siRNAs: 5-GAACAGAUGUGUCCUAUUU-3, 5-GAGCUCAA-
CUCCAGUAUAUUG-3, 5-AGAAGAAGCUUUAGCAAUU-3, and 5-GCU-
GAAAGGUCAACAGAUA-3. INTERFERin transfection reagent (Polyplus 
Transfection, Inc.) was used for transfections according to the manufactur-
er’s instructions. Effects of depletion were assayed 3 d after transfection. 
cDNAs encoding untagged full-length MarvelD3 isoforms and full-length 
Occludin were expressed using pcDNA4 and pCB6 expression vectors; 
both vectors have cytomegalovirus promoters for eukaryotic expression 
(Balda et al., 1996; Steed et al., 2009). Vesicular stomatitis virus (VSV)–
tagged versions of full-length and truncated cDNAs were constructed as 
described by adding the VSV epitope tag (i.e., GYTDIEMNRLGK) to the 
C-terminal end of the full-length cDNAs and were then then expressed 
using pcDNA4 (Benais-Pont et al., 2003). The mouse MarvelD3 isoform 1 
cDNA was amplified from total RNA isolated from mouse intestine using 
the primers 5-CCGGAATTCCGATGAAAAATACTTCGGGGCAC-3 and 
5-ATGCAGTGGCTAGCGAGCGTCCCGGACCACAGGTATTC-3 and 
cloned into pCIN4-VSV. MarvelD3/biotin ligase fusion proteins were gen-
erated using the plasmids described by Roux et al. (2012) for N- and 
C-terminal fusions by cloning the full-length MarvelD3 isoform 1 cDNA into 
pcDNA3.1-mycBirA-R118G and pcDNA3.1-mycBirA-R118G. For the pro-
duction of His6-tagged MEKK1 fusion proteins, fragments were amplified 
from a rat MEKK1 cDNA (provided by M. Cobb, University of Texas South-






CAGGATG-3. For expression experiments, plasmids were transfected into 
Caco-2 and MiaPaca-2 cells using transfection reagent (jetPEI; Polyplus 
Transfection, Inc.) according to the manufacturer’s instructions. For the gen-
eration of stable cell lines, MiaPaca-2 cells plated at 50% confluence in 
complete medium with 2.5% horse serum (Invitrogen) were transfected 
24 h later with 20 µg pCIN4-MD3_1:VSV and incubated for 8 h at 37°C. 
Cells were then trypsinized, resuspended in 25 ml complete medium, and 
plated onto 15-cm plates and selected with 0.6 mg/ml G418. After 17 d, 
clones were picked and plated in complete medium containing 0.6 mg/ml 
G418. Transfection efficiency was determined by immunoblotting and 
immunofluorescence. Expression of MD3_1:VSV was established in two inde-
pendent clones (C2 and C8). MD3–MiaPaca-2 C2 and C8 were cultured 
in DMEM containing 10% FBS and 3 mg/ml G418. All experiments were 
performed in the absence of G418. Fluorescent MiaPaca-2 cells were gen-
erated using lentiviral vectors expressing humanized GFP or RFP under the 
control of a spleen focus-forming virus promoter (Georgiadis et al., 2010). 
Viral packaging using pMD2VSVG was performed as previously described 
(Sourisseau et al., 2006). Caco-2 cell lines were generated with calcium 
phosphate transfections as previously described (Matter et al., 1992). Re-
verse transcription was performed on total RNA isolated from MiaPaca-2 
cells and pancreatic RNA (Takara Bio Inc.) at 45°C using avian myoblas-
tosis virus reverse transcription (Promega) for 1 h. The cDNAs were then 
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measures of the tumor, respectively (Tomayko and Reynolds, 1989). At the 
end of experiments, mice were sacrificed by cervical dislocation, and tu-
mors were excised for imaging.
Impedance measurements
Impedance was measured in response to hyperosmotic shock using an 
Electric Cell-Substrate Impedance Sensing system (model 1600R; Applied 
BioPhysics). Control and MD3p siRNA–transfected Caco-2 cells were 
plated into an Electric Cell-Substrate Impedance Sensing electrode array 
containing 10 electrodes per well (8W10E; Applied BioPhysics). Array 
plates were first cleaned with 200 µl per well of 10 mM cysteine for 10 min 
and then washed three times with PBS. Cells were plated in quadruplicate 
and grown at 37°C for 48 h until confluent. Basal impedance across the 
monolayer was measure at 37°C for 1 h. Complete medium was then re-
placed with hypertonic medium (600 mOsm), and measurements of imped-
ance were taken at 2-min intervals for a further 10 h.
Reporter assays
Cells were plated in 96-well plates in complete medium the day before 
transfection. For overexpression experiments, cells were cotransfected with 
cDNA encoding full-length MarvelD3 isoform 1, isoform 2, or Occludin or 
empty pCB6 vector (control) alongside a firefly luciferase reporter construct 
and Renilla luciferase control plasmid, with jetPEI reagent. The AP1 and 
SRE firefly luciferase reporter constructs were obtained from Takara Bio 
Inc., and the T cell factor/-catenin reporter plasmid was obtained from 
Merck EMD Millipore. The ZONAB firefly reporter plasmid contained a 
minimal ErbB-2 promoter (396 to 150 in pXb-1), and the Renilla control 
plasmid contained an analogous ErbB-2 promoter in pRL but in which the 
ZONAB binding site had been inactivated by substituting the inverted 
CCAAT box (Frankel et al., 2005). The cyclin D1 reporter plasmid con-
tained a 1.7-kb promoter fragment in pXb1 (Sourisseau et al., 2006). 
Transfection mix was changed for fresh medium 24 h after transfection. Lu-
ciferase luminescent signals were determined 24 h later using the assay kit 
(Dual-Luciferase Reporter; Promega). Firefly and Renilla luciferase lumines-
cent signals were measured sequentially using a microplate reader (FLUO-
star OPTIMA; BMG Labtech). Relative promoter activity was calculated by 
making a ratio between luciferase and Renilla luminescent signals and then 
normalizing to control transfections. For knockdown experiments, cells 
were transfected with siRNA 24 h after plating, and medium was changed 
after 24 h and transfected with reporter constructs another 24 h later. 
Transfection mix was changed for fresh medium 24 h later, and lumines-
cence signals were read after a further 8 h.
Statistical analysis
Means and SDs were calculated and provided in the graphs. Respective 
n values are provided in the figure legends. The indicated p-values were 
obtained with two-tailed Student’s t test.
Online supplemental material
Fig. S1 shows the effect of MarvelD3 siRNAs on proliferation and migration 
of MiaPaca-2 and MCF7 cells. Fig. S2 shows the effect of ectopic MarvelD3 
expression in MiaPaca-2 cells and other junctional proteins by immunofluor-
escence and immunoblotting as well as intermixing of MiaPaca-2 cells in 
the presence or absence of MarvelD3 expression. Fig. S3 shows the effect 
of osmotic shock on MarvelD3 expression levels in the presence of cyclo-
heximide, double immunofluorescence of MarvelD3 with endocytic mark-
ers, quantification of MarvelD3 and Occludin localization during osmotic 
shock, and the distribution of Occludin in MarvelD3-depleted cells after 
2 h of hypertonic shock. Fig. S4 shows the localization of MEKK1 in para-
formaldehyde-fixed cells and quantification of MEKK1 localization dur-
ing osmotic shock. Fig. S5 shows the activation profiles of p38 and Erk 
in control and MarvelD3-depleted Caco-2 cells in response to osmotic shock, 
c-Jun mRNA levels and protein stability in control, and MarvelD3-depleted 
cells, quantification of TUNEL-positive cells in response to JNK inhibitor and 
osmotic shock, and attenuation of junction disassembly by JNK inhibition 
in MarvelD3-depleted cells. Online supplemental material is available at 
http://www.jcb.org/cgi/content/full/jcb.201304115/DC1.
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transferred to nitrocellulose or polyvinylidene difluoride membranes, and 
bound primary antibodies were detected with horseradish peroxidase–
conjugated secondary antibodies and an ECL detection system (ECL; GE 
Healthcare) or with IRDye680- and IRDye800-labeled secondary antibod-
ies and an infrared scanner (Odyssey; LI-COR Biosciences; Elbediwy et al., 
2012). Immunoblots were quantified with ImageJ, and the provided n num-
bers refer to analyzed experiments.
GST pull-downs and isolation of biotinylated proteins
Fragments encoding the N-terminal domain and isoform-specific C-terminal 
domains (CTD1 and CTD2) of MarvelD3 were cloned in to pGEX-4T-3 GST 
fusion vector. Fusion proteins were produced by transforming plasmids into 
competent BL21 pLysS cells, and production was induced by the addition 
of 1 mM isopropyl -d-1-thiogalactopyranoside and incubation at 25°C for 
2 h. Fusion proteins were then recovered by lysing cells in PBS containing 
0.5% Triton X-100 (PBSTx) and a cocktail of protease and phosphatase in-
hibitors (50 µg/ml benzamidine, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 
10 µg/ml pepstatin A, and 1 mM PMSF) and 1 mM DTT. Samples were 
sonicated and centrifuged at 10,000 rpm, and the supernatant was stored 
at 80°C until use. To identify interaction partners and the responsible do-
mains of MarvelD3, GST fusion proteins were conjugated to glutathione 
beads for 2 h at 4°C. Extracts of Caco-2 cells grown on 15-cm cell culture 
dishes until 80% confluent were generated with PBS containing 0.5% Triton 
X-100 (PBSTx) and preabsorbed with unconjugated Sepharose beads. The 
extracts were then incubated with the beads carrying the GST fusion pro-
teins for 2 h at 4°C. The samples were washed once in PBSTx and twice in 
PBS before being separated by SDS-PAGE. For recombinant protein-binding 
assays, the His6-tagged protein was added to the GST fusion protein bound 
to beads. After an overnight incubation at 4°C, the beads were washed 
twice with PBSTx before immunoblotting. For the isolation of biotinyl-
ated proteins, cells were extracted with 10 mM Hepes, pH 7.4, containing 
150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.2% 
sodium dodecylsulfate, and a cocktail of protease inhibitors. After centrifu-
gation, the extracts were loaded on streptavidin–agarose beads and, after 
2 h, washed four times with extraction buffer and once with PBS.
Migration assays
To assess cell migration, MiaPaca-2 and Caco-2 cells were applied to both 
0.22-mm2 chambers of a 9 × 9 × 5–mm culture insert (µ-Dish; ibidi) in 70 µl 
complete medium. For knockdown experiments, cells were transfected in 
24-well plates and transferred to culture inserts 24 h later. In all experi-
ments, when confluent, inserts were gently removed to reveal a 500-µm 
cell-free space between monolayers, and the medium was replaced with 
fresh complete medium containing mitomycin c to inhibit proliferation. 
Phase-contrast images were taken at regular time points until the most rap-
idly migrating cells showed 80% wound closure. Quantification of wound 
closure was made using ImageJ software (percentage of wound closure = 
100  [(cell-free area at end point)/(cell-free area at time 0) × 100].
Proliferation and cell death assays
To assess proliferative behavior in vitro, MiaPaca-2 or Caco-2 cells (control 
and depleted of MarvelD3 by siRNA transfection) were plated in triplicate 
into 96-well plates at equal cell densities. Medium was removed after 3 d, 
and samples were frozen at 80°C. Cell numbers were quantified the next 
day using a CyQUANT Cell Proliferation Assay kit (Invitrogen) according 
to the manufacturer’s instructions. Fluorescence was determined using a 
microplate reader and converted into cell numbers against a reference 
standard curve for each cell type. For inhibition of JNK experiments, cells 
were incubated in medium containing 0.2% FBS for 24 h, plus 20 µM 
SP600125 or DMSO for the last 3 h. Complete medium containing 
SP600125 or DMSO was then added for an additional 24 h, and cell 
number was quantified. Induction of apoptosis and necrosis was assayed 
measuring caspase 3/7 activities and release of lactate dehydrogenase 
activity, respectively, using the respective fluorescent assay kits obtained 
from Promega (Nie et al., 2012). The DeadEnd Fluorometric TUNEL Sys-
tem obtained from Promega was used for the TUNEL analysis.
Xenografts
Mice were raised and treated according to the principles of laboratory ani-
mal care of the University Animal Welfare Committee. After a 7-d adapta-
tion period, 6–8-wk-old female athymic nude mice (Harlan Laboratories) 
were injected subcutaneously into the right flank region with 5 × 106 Mia-
PaCa-2 cells suspended in PBS containing 50% growth factor–reduced 
Matrigel (BD; Kyriazis and Kyriazis, 1980). Tumor growth was monitored 
with a digital caliper, and their volume was estimated according to the fol-
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